Ionis Pharmaceuticals, Inc.

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Current securities

1. Regulation FD Disclosure · Other EventsSep 23, 2026
2. Regulation FD Disclosure · Other EventsSep 4, 2026
3. Regulation FD Disclosure · Other EventsSep 4, 2026
4. S-8 filingJul 31, 2026
5. 10-Q filingJul 29, 2026